"We are excited to welcome Cris to the Regulus team," said Jay Hagan CEO of Regulus. "Cris brings a strong track record of execution to the Regulus senior management team and I look forward to working with her as we advance our pipeline of microRNA therapeutics."
"I am privileged and eager to join the Regulus leadership team at such a pivotal time for the business," said
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the advancement of Regulus' preclinical and clinical activities, including statements regarding the timing of preclinical and clinical activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and feedback from the FDA. These and other risks are described in additional detail in Regulus' filings with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/regulus-therapeutics-appoints-cris-calsada-as-chief-financial-officer-300892826.html
Turner Jenkins, Senior Director, Corporate Development, 858-202-6378, email@example.com